WO2004035011A3 - Botulinum toxin dental therapies and procedures - Google Patents

Botulinum toxin dental therapies and procedures

Info

Publication number
WO2004035011A3
WO2004035011A3 PCT/US2003/032841 US0332841W WO2004035011A3 WO 2004035011 A3 WO2004035011 A3 WO 2004035011A3 US 0332841 W US0332841 W US 0332841W WO 2004035011 A3 WO2004035011 A3 WO 2004035011A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
therapies
toxin
procedures
dental
administration
Prior art date
Application number
PCT/US2003/032841
Other languages
French (fr)
Other versions
WO2004035011A2 (en )
Inventor
Howard I Katz
Andrew M Blumenfeld
Original Assignee
Allergan Inc
Howard I Katz
Andrew M Blumenfeld
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria

Abstract

Methods for facilitating various dental treatments, therapies and procedures by administration of a Clostridial toxin to a muscle or other tissue on the head or neck of a patient.
PCT/US2003/032841 2002-10-15 2003-10-14 Botulinum toxin dental therapies and procedures WO2004035011A3 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US41878902 true 2002-10-15 2002-10-15
US60/418,789 2002-10-15
US10/685,986 2003-10-14
US10685986 US20040115139A1 (en) 2002-10-15 2003-10-14 Botulinum toxin dental therapies and procedures

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20030781333 EP1551430A2 (en) 2002-10-15 2003-10-14 Botulinum toxin dental therapies and procedures
JP2004545397A JP2006513994A (en) 2002-10-15 2003-10-14 Botulinum toxin dental treatment and dental measures
CA 2501856 CA2501856A1 (en) 2002-10-15 2003-10-14 Botulinum toxin dental therapies and procedures

Publications (2)

Publication Number Publication Date
WO2004035011A2 true WO2004035011A2 (en) 2004-04-29
WO2004035011A3 true true WO2004035011A3 (en) 2004-09-23

Family

ID=32110188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/032841 WO2004035011A3 (en) 2002-10-15 2003-10-14 Botulinum toxin dental therapies and procedures

Country Status (6)

Country Link
US (2) US20040115139A1 (en)
EP (1) EP1551430A2 (en)
JP (1) JP2006513994A (en)
KR (1) KR20050061541A (en)
CA (1) CA2501856A1 (en)
WO (1) WO2004035011A3 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2413301A1 (en) * 2000-06-28 2002-01-03 Ira Sanders Methods for using tetanus toxin for benificial purposes in animals (mammals)
US20040104108A1 (en) * 2002-12-03 2004-06-03 Mason Robert Michael High capacity purification of thermally unstable compounds
US7311103B2 (en) * 2003-07-29 2007-12-25 Checkmate Holding Company, Llc Method for treating obstructive sleep apnea syndrome
US7811584B2 (en) * 2004-06-30 2010-10-12 Allergan, Inc. Multivalent clostridial toxins
EP1784420B1 (en) 2004-09-01 2008-12-03 Allergan, Inc. Degradable clostridial toxins
JP2008532549A (en) 2005-03-15 2008-08-21 アラーガン、インコーポレイテッドAllergan,Incorporated Modified Clostridial toxin with a targeting capability increased to endogenous Clostridial toxin receptor system
US7514088B2 (en) * 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
US20060246093A1 (en) * 2005-04-13 2006-11-02 Biomed Est. Implant analog
US20080021437A1 (en) * 2006-04-27 2008-01-24 Boyd James P Enhancement of the efficacy of a clenching reduction device by augmenting with botulinum toxin type A
WO2011011513A1 (en) * 2009-07-21 2011-01-27 University Of Washington Through Its Center For Commercialization Inhibition of pathological bone formation
US9125907B2 (en) 2009-09-30 2015-09-08 Christopher Shaari Use of botulinum neurotoxin to treat substance addictions
US8696352B2 (en) 2011-09-15 2014-04-15 Lanfried Ortho Technology, Llc Intra-oral appliance and methods of using same
US9744000B2 (en) 2011-09-15 2017-08-29 Lanfried Ortho Technology, Llc Intra-oral appliance and methods of using same
EP2779939B1 (en) * 2011-11-15 2018-02-14 Trispera Dental Inc. Method and system for acquiring data from an individual for preparing a 3d model
US9005628B2 (en) 2012-10-04 2015-04-14 Dublin City University Biotherapy for pain
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
WO2016073792A1 (en) * 2014-11-06 2016-05-12 Matt Shane Three dimensional imaging of the motion of teeth and jaws
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
WO2018060351A1 (en) 2016-09-29 2018-04-05 Ipsen Biopharm Limited Hybrid neurotoxins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298019A (en) * 1990-08-21 1994-03-29 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
WO2002040506A2 (en) * 2000-11-17 2002-05-23 Allergan Inc. Modified clostridial neurotoxins with altered biological persistence

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5437291A (en) * 1993-08-26 1995-08-01 Univ Johns Hopkins Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction
US6974578B1 (en) * 1993-12-28 2005-12-13 Allergan, Inc. Method for treating secretions and glands using botulinum toxin
DE69435194D1 (en) * 1993-12-28 2009-04-16 Allergan Sales Inc Use of botulinum toxin type B for the manufacture of a medicament for reduction of pain due to muscle disease
US5766605A (en) * 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
US5670484A (en) * 1994-05-09 1997-09-23 Binder; William J. Method for treatment of skin lesions associated with cutaneous cell-proliferative disorders
DE69526340D1 (en) * 1994-05-09 2002-05-16 William J Binder Botulinum toxin FOR REDUCING Migraine Headache
GB9508204D0 (en) * 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) * 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
US6063768A (en) * 1997-09-04 2000-05-16 First; Eric R. Application of botulinum toxin to the management of neurogenic inflammatory disorders
US6164278A (en) * 1999-02-25 2000-12-26 Nissani; Moti Taste-based approach to the prevention of teeth clenching and grinding
US6358917B1 (en) * 1999-08-24 2002-03-19 Jean D. A. Carruthers Cosmetic use of botulinum toxin for treatment of downturned mouth
US6265379B1 (en) * 1999-10-13 2001-07-24 Allergan Sales, Inc. Method for treating otic disorders
US6139845A (en) * 1999-12-07 2000-10-31 Allergan Sales, Inc. Method for treating cancer with a neurotoxin
US6464986B1 (en) * 2000-04-14 2002-10-15 Allegan Sales, Inc. Method for treating pain by peripheral administration of a neurotoxin
US6299893B1 (en) * 2000-04-17 2001-10-09 Marvin Schwartz Method to reduce hair loss and stimulate hair regrowth
US6306423B1 (en) * 2000-06-02 2001-10-23 Allergan Sales, Inc. Neurotoxin implant
US6423319B1 (en) * 2000-10-04 2002-07-23 Allergan Sales, Inc. Methods for treating muscle injuries
US20020192239A1 (en) * 2001-01-09 2002-12-19 Borodic Gary E. Use of botulinum toxin for the treatment of chronic facial pain

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5298019A (en) * 1990-08-21 1994-03-29 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
WO2002040506A2 (en) * 2000-11-17 2002-05-23 Allergan Inc. Modified clostridial neurotoxins with altered biological persistence

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHIKHANI L ET AL: "Bruxisme, syndrome algodysfonctionnel des articulations temporo-mandibulaires et toxine botulique." ANNALES DE READAPTATION ET DE MEDECINE PHYSIQUE, vol. 46, no. 6, 2003, pages 333-337, XP002273048 ISSN: 0168-6054 (ISSN print) *
KAÑOVSKY P ET AL: "Treatment of facial and orolinguomandibular tardive dystonia by botulinum toxin A: evidence of a long-lasting effect." MOVEMENT DISORDERS: OFFICIAL JOURNAL OF THE MOVEMENT DISORDER SOCIETY. UNITED STATES SEP 1999, vol. 14, no. 5, September 1999 (1999-09), pages 886-888, XP009027402 ISSN: 0885-3185 *
UMSTADT H E: "[Botulinum toxin in oromaxillofacial surgery]" MUND-, KIEFER- UND GESICHTSCHIRURGIE: MKG. GERMANY JUL 2002, vol. 6, no. 4, July 2002 (2002-07), pages 249-260, XP002273049 ISSN: 1432-9417 *

Also Published As

Publication number Publication date Type
US20060018844A1 (en) 2006-01-26 application
WO2004035011A2 (en) 2004-04-29 application
KR20050061541A (en) 2005-06-22 application
JP2006513994A (en) 2006-04-27 application
EP1551430A2 (en) 2005-07-13 application
CA2501856A1 (en) 2004-04-29 application
US20040115139A1 (en) 2004-06-17 application

Similar Documents

Publication Publication Date Title
WO2005074913A3 (en) Compositions and methods for treating contracture
Thase Achieving remission and managing relapse in depression.
WO1998025508A3 (en) Staple and staple applicator for use in skin fixation of catheters
WO2005028029A3 (en) Patient monitoring, diagnosis, and/or therapy systems and methods
WO2004019863A3 (en) Combination therapy for treatment of fibrotic disorders
WO2005089502A3 (en) Methods for the treatment of synucleinopathies
WO2005011769A3 (en) Implantable or insertable medical devices containing acrylic copolymer for controlled delivery of therapeutic agent
CA2532804A1 (en) Substituted 2-aminotetralin for the treatment of depression
WO2003032994A3 (en) Novel tri-substituted pyrimidines, method for production and use thereof as medicament
WO2004047677A3 (en) Methods and apparatus for remodeling an extravascular tissue structure
WO2004041067A3 (en) Prevention and treatment of synucleinopathic disease
WO2003051374A3 (en) SEQUESTRATION OF Aβ IN THE PERIPHERY IN THE ABSENCE OF IMMUNOMODULATING AGENT AS A THERAPEUTIC APPROACH FOR THE TREATMENT OR PREVENTION OF BETA-AMYLOID RELATED DISEASES
WO2002011667A3 (en) Pharmaceutical compositions and methods useful for modulating angiogenesis
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2002021141A3 (en) Methods and compositions for diseases associated with amyloidosis
CA2549642A1 (en) Effervescent oral opiate dosage forms and methods of administering opiates
WO2004014367A3 (en) Use of an amyloid beta vaccination in combination with a selective cox-2 inhibitor for the treatment of alzheimer's disease
CA2451258A1 (en) Combination therapy of substituted oxazolidinones
WO2004072031A8 (en) Phenylacetamides and their use as glucokinase modulators
WO2002096367A3 (en) Targeted multivalent macromolecules
WO2005041921A3 (en) Dry powder compositions for inhalation therapy comprising calcium stearate, medical devices therefor
WO2001028535A3 (en) Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate
WO2003028558A8 (en) Methods and devices for heart valve treatments
CN2538330Y (en) Acupoint pressing pillow
WO2001074314A3 (en) Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003287155

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 539081

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2003781333

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2501856

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/003936

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004545397

Country of ref document: JP

Ref document number: 1020057006505

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 1020057006505

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2003781333

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2003781333

Country of ref document: EP